Pharmacist intervention may help identify potential opioid abuse early

Concurrent drug utilization review (DUR) may cast wider net for catching potential opioid abuse upstream

A pharmacist intervention (DUR) may impact potential opioid misuse and abuse. This study identified at-risk members at the time they submit their opioid prescription. A soft edit (point of service) intervention delayed or altered claims for 42% of the members in the study.

Impact of a Concurrent Drug Utilization Review Edit Designed to Curb Opioid Misuse (Spring 2016)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

July 25, 2024

Quarterly Drug Pipeline: July 2024

Clinical insights and competitive intelligence on anticipated drugs in development

Perspectives

July 22, 2024

Oncology Insights: 2024 ASCO Annual Meeting key findings

Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions

Perspectives

July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts

View all news